Anzeige
Mehr »
Login
Freitag, 08.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
4.000 Meilen, um herauszufinden, warum der „Warren Buffett des Bergbaus" in diese Kupferaktie investierte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
604 Leser
Artikel bewerten:
(2)

Wolters Kluwer N.V.: Wolters Kluwer appoints Greg Samios as President & CEO of Clinical Effectiveness, Dr. Peter Bonis as Chief Medical Officer for the Health division

Wolters Kluwer appoints Greg Samios as President & CEO of Clinical Effectiveness,
Dr. Peter Bonis as Chief Medical Officer for the Health division

November 11, 2021 -Wolters Kluwer Healthannounces the appointments of Gregory Samios as President & CEO of Clinical Effectiveness and Dr. Peter Bonis as Chief Medical Officer (CMO) of the division, effective December 1, 2021. The appointments reflect Wolters Kluwer's continued focus on advancinghealthcare technology and growing expert solutions across the continuum of healthcare.

As President and CEO for Clinical Effectiveness, the largest business within Wolters Kluwer's Clinical Solutions group, Samiossucceeds Dr. Denise Basow, who is leaving Wolters Kluwer after 25 years of service. Samios brings decades of experience as a customer-focused executive in the healthcare and legal information sectors. Most recently, he served as President and CEO of Health Learning, Research & Practice (HLRP). Throughout his career, Samios has been passionate about working together with customers to understand their unique challenges and deliver deep impact where it matters most. He employs lean principles to all aspects of business transformation to stimulate innovation and cultivate industry partnerships as vital to building value creation. Samios joined Wolters Kluwer in 2014, serving as President and CEO of the Wolters Kluwer Legal & Regulatory U.S. business before moving to the Health Division to lead HLRP in 2019. Previously, he held executive leadership roles at Kaplan Test Prep and Admissions, Reed Elsevier, Excerpta Medica, and Elsevier Health Sciences. Samios earned an MBA at Duke University and graduated from the University of Rochester with a B.S. and M.S. in Engineering.

Dr. Bonis, who has served as Chief Medical Officer of Clinical Effectiveness since 2015, will now expand his scope to oversee division-wide industry partnerships, research and development initiatives, and deep collaborations with customers and partners. He joined Wolters Kluwer in 2008 as part of the acquisition of UpToDate where he has served since 1998. He was instrumental to the development of UpToDate into the leading clinical decision support tool used by doctors globally and in bringing our drug information and patient engagement products together with UpToDate under Clinical Effectiveness. Dr. Bonis is a graduate of Harvard University and New York University School of Medicine. He was an assistant professor at Yale University School of Medicine and is currently an adjunct professor of medicine at Tufts University School of Medicine.

"Healthcare technology is rapidly changing the ways patients receive care, how clinicians make better decisions, and even how students learn to practice. I am excited to work with Greg and Peter in their new expanded roles to accelerate the innovation and customer success we deliver across our solutions at such an important time in the industry and global healthcare markets," said Stacey Caywood, Chief Executive Officer, Wolters Kluwer Health.

The Clinical Effectiveness business, which is part of Clinical Solutions, includes our UpToDate clinical decision support solutions, Lexicomp and Medi-Span clinical drug information, and the Emmi patient engagement solutions.

###

About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.

Wolters Kluwer reported 2020 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,200 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/healthand follow us on LinkedInand Twitter @WKHealth.

For more information, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.

Media
André Rebelo
Sr. Global Public Relations Manager
Wolters Kluwer Health
+1

Attachment

  • 2021.11.11 Wolters Kluwer appoints Greg Samios as President CEO of Clinical Effectiveness Dr. Peter Bonis as Chief Medical Officer for the Health div (https://ml-eu.globenewswire.com/Resource/Download/98066daf-262d-4144-83eb-574638501bee)

© 2021 GlobeNewswire (Europe)
Treibt Nvidias KI-Boom den Uranpreis?
In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.